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Background/aim: DNA topoisomerases are ubiquitous enzymes that regulate conformational changes in DNA topology during essential
cellular processes, and, for this reason, have been characterized as the cellular targets of a number of anticancer drugs. Bortezomib is a
powerful proteasome inhibitor used in the treatment of hematological malignancies. In this study, we investigated the inhibitory effects
of bortezomib on human topoisomerase I and II enzymes both alone and in combination modes with camptothecin and etoposide.
Materials and methods: The interactions of these drugs with topoisomerase enzymes were evaluated by relaxation assay in cell-free
systems. IC50 values of the drugs on topoisomerase enzymes were calculated using the S probit analysis program.
Results: Bortezomib showed a very weak inhibition effect on topoisomerase I (IC50 = 87.11 mM). On the other hand, it had a strong
inhibitory effect on topoisomerase II (IC50 = 1.41 mM). Our results indicated that bortezomib is effective not only on proteasome but
also on topoisomerase II. In addition, bortezomib possesses an increased synergistic effect when used in combination with camptothecin
and etoposide than when used alone.
Conclusion: The results of this study point out that these data may build a framework for combination studies with bortezomib,
camptothecin, and etoposide in the treatment of cancer.
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1. Introduction
Bortezomib (PS-341) is a dipeptide boronic acid analogue
with antineoplastic activity. Bortezomib reversibly
inhibits the 26S proteasome, a large protease complex
that degrades ubiquitinated proteins. The ubiquitin–
proteasome pathway plays an essential role in regulating
the intracellular concentration of specific proteins, thereby
maintaining homeostasis within cells. Inhibition of the
26S proteasome prevents this targeted proteolysis, which
can affect multiple signaling cascades within the cell.
This disruption of normal homeostatic mechanisms can
lead to cell death. By blocking the targeted proteolysis
normally performed by the proteasome, bortezomib
disrupts various cell signaling pathways, leading to cell
cycle arrest, apoptosis, and inhibition of angiogenesis. In
vivo, bortezomib delays tumor growth and enhances the
cytotoxic effects of radiation and chemotherapy (1,2).
Tumor cells, that is, rapidly dividing cells, appear to be more
sensitive to proteasome inhibition. Bortezomib (Velcade,
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA)
is the first proteasome inhibitor anticancer drug approved
* Correspondence: emineoksuzoglu@hotmail.com
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in the USA by the Food and Drug Administration (FDA)
for the treatment of newly diagnosed multiple myeloma
and relapsed/refractory multiple myeloma and mantle cell
lymphoma (3–5).
DNA topoisomerases are ubiquitous enzymes that
control and modify the topological states of DNA. They
can catalyze several interconversions between topological
isomers of DNA by transiently breaking single or double
strands, and resealing them after reorganization of the
topology (6). Depending on the nature of the reactants
and reaction conditions, topoisomerases can catalyze
DNA relaxation/supercoiling, catenation/decatenation,
and knotting/unknotting reactions (7,8). Based on their
functional mechanisms, DNA topoisomerases have been
classified into two types. Type I DNA topoisomerase breaks
and rejoins only one of the two strands during catalysis,
while type II DNA topoisomerase acts on both strands for
each DNA strand-passing reaction and it requires ATP for
full activity (9,10). Since the activity of topoisomerases is
essential for several cellular processes such as replication,
transcription, and chromosome condensation, inhibitory
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activities of eukaryotic topoisomerases are widely used in
anticancer drug development (11).
Topoisomerase inhibitors could be divided into
two main groups, i.e. poisons and catalytic inhibitors.
Topoisomerase poisons stabilize the DNA-enzyme
cleavable complex, which is normally temporary, and
breaks DNA ends bounded immediately after altering
of topological state and they can trap this complex to
cause DNA strand breaks. If the amount of these DNA
breaks is intolerable, stability of DNA could be disrupted
and apoptosis might be induced in the cells. Catalytic
inhibitors block one or more steps of the catalytic cycle
of the topoisomerases (12). Both kinds of inhibitors are
commercially available for cancer treatment.
Camptothecin (CPT) is the best known topoisomerase
I inhibitor. Camptothecin is a potent anticancer drug that
has shown clinical activity in human tumors such as colon
and ovarian cancers and is approved by the FDA. Studies
suggested that camptothecin not only stabilized the
cleavable complex, but also inhibited the relegation step of
the catalytic cycle of topoisomerase I (13,14).
Etoposide is an important chemotherapeutic agent that
is used to treat a wide spectrum of human cancers. It has
been in clinical use for more than two decades and remains
one of the most highly prescribed anticancer drugs in
the world. The primary cytotoxic target for etoposide is
topoisomerase II. Etoposide is a potent antitumor drug
that was approved by the FDA for the treatment of various
tumors such as small-cell lung cancer, breast cancer,
leukemia, lymphoma, and the germ-line cancers (15).
Bortezomib, the potent therapeutic proteasome
inhibitor, has been suggested for standard care in patients
with newly diagnosed or relapsed multiple myeloma and
several lymphoma subtypes (3–5). However, intrinsic
and acquired resistance to bortezomib and toxicities may
limit its efficacy. The discovery and development of new
treatments are urgently needed due to the problems of
current treatments, such as toxicities and drug-resistance.
Drug combination is the most widely used approach in
treating numerous dreadful diseases, such as cancer (16).
Bortezomib is a proteasome inhibitor anticancer drug.
However, the inhibitory effect of bortezomib on human
topoisomerase enzymes has remained insufficiently
determined. In this study, bortezomib was applied in
combination with topoisomerase I inhibitor camptothecin
and topoisomerase II inhibitor etoposide. These inhibitors
are widely used antitumor drugs that were approved by
the FDA for the treatment of various cancers. However,
the combined applications of these drugs were not studied
sufficiently.
For this reason, we investigated the inhibitory effects
of bortezomib on human topoisomerase I and II enzymes
both alone and in combination modes with camptothecin
and etoposide.

2. Materials and methods
2.1. Materials
Human topoisomerase I and II relaxation assay kits were
purchased from Inspiralis UK. Bortozomib was obtained
from Velcade (Johnson & Johnson Pharmaceutical
Research and Development, Raritan, NJ, USA),
camptothecin, etoposide, reagents for electrophoresis and
the other chemicals were obtained from Sigma (Munich,
Germany). Solutions of the tested compounds in 50%
dimethyl sulfoxide (DMSO) were freshly prepared.
2.2. Topoisomerase I and II relaxation assay
We implemented the relaxation assay to test the topo
I and II inhibition effect of the bortezomib and also
combine the effect of proteosome and topoisomerase
inhibitors in cell-free systems (13). Relaxation activity of
topoisomerase enzymes was determined by measuring
the conversion of supercoiled pBR322 plasmid DNA to
its relaxed form (10). If the tested compounds interrupt
this process, DNA remains in its supercoiled form. At
this point, supercoiled DNA band intensities could be
compared with its control.
For topo I the reaction mixture contained 1 µL of
10X assay buffer [20 mM Tris HCl pH = 7.5, 200 mM
NaCl, 0.25 mM EDTA, 5% glycerol] , 0.3 µg of pBR322
plasmid DNA, 3 units of topo I enzyme, and different
concentrations of test compounds in a total volume 10
µL.
For topo II the reaction mixture contained 1 µL of 10X
assay buffer [50 mM Tris HCl pH = 7.5, 125 mM NaCl,
10 mM MgCl2, 5 mM DTT, 100 µg/mL albumin, 1 mM
ATP], 0.3 µg of pBR322 plasmid DNA, 3 units of topo II
enzyme, and different concentrations of test compounds
in a total volume 10 µL. Both of the reaction mixtures
were incubated for 1 h at 37 °C. After the incubation
period, 2 µL of 6X loading buffer was added and the
mixtures were subjected to electrophoresis on 1% agarose
at 45 V for 3 h. After electrophoresis the gels were stained
with ethidium bromide (1 µg/mL), photographed under
UV light, and band distribution was analyzed with a gel
analysis system (Bio-Rad) (8,10,13,17).
2.3. Statistical analysis
Optical intensity of the newly formed bands was used
as a measure of enzyme activity. Moreover, topo I and II
inhibition percentage of the compounds was calculated
by comparing supercoiled DNA band intensities of the
control (18). Optical intensity of each concentration of the
compounds was compared with the control to calculate
inhibition percentages. With these percentages, IC50 (50%
inhibition concentrations) values of the compounds were
calculated using the S probit analysis program. According
to the literature, a compound with 50% inhibitory effect
on topoisomerases could be regarded as an inhibitor (19).
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3. Results
Human topoisomerase I and II activities in cell-free systems
were evaluated by the relaxation assay as described above.
The relaxation assay utilizes supercoiled plasmid DNA as a
substrate and has been used by many investigators to study
inhibition of DNA topoisomerase I and II activities (20–23).
The supercoiled substrate and its relaxed state can easily
be distinguished in ethidium bromide stained gels since
relaxed isomers migrate more slowly than the supercoiled
isomer. The change in the molecular shape without a
change in the molecular weight can be differentiated,
since more compact molecules move faster compared with
their more relaxed counterparts. If the DNA molecules
were completely relaxed by topoisomerases and there is
equilibrium between the different topological forms of
the DNA molecules, then at the end of the electrophoresis
several bands would be obtained. However, if the catalytic
activities of topoisomerases were inhibited by the tested
compounds, all the DNA molecules, therefore, were in the
supercoiled form.
In this study, we primarily identified their inhibitory
effects and IC50 values using different concentrations of
topoisomerase I inhibitor camptothecin and topoisomerase
II inhibitor etoposide, which are used as powerful drugs
for therapeutic purposes in various cancers. Inhibition
concentrations of these drugs were determined by applying
a large dose range during experiment optimization.
Inhibitory activities of the compounds were presented as
mM concentrations that cause 50% inhibition per unit of
enzyme (IC50) under the assay conditions. Camptothecin
and etoposide were found to be potent human DNA
topoisomerase I and II inhibitors, having IC50 values of
0.29 mM and 3.77 mM, respectively (Table; Figures 1 and 2).
Bortezomib is a powerful proteasome inhibitor
anticancer drug that is used in the treatment of
hematological cancers. However, the inhibitory effect
of bortezomib on human topo I and II enzymes has
remained insufficiently determined so far in other studies.
Therefore, it is interesting to undertake further studies
to approach such effects. We investigated the inhibitory
effects of bortezomib on human topoisomerase I and II
enzymes applying four different concentrations (0.25, 0.5,
Table. IC50 values of the tested compounds for human
topoisomerase I and II enzymes.
Compounds

Topo I IC50 (mM)

Topo II IC50 (mM)

Camptothecin

0.29 mM

NE

Etoposide

NE

3.77 mM

Bortezomib

87.11 mM

1.41 mM

NE: Not effective
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Figure 1. The inhibitory effect of camptothecin on human
topoisomerase I. Lane 1: supercoiled pBR322 plasmid DNA (0.3
µg) without enzyme. Lane 2: plasmid DNA with 3 units of topo I
enzyme (control). Lanes 3–7: plasmid DNA with 3 units of topo
I enzyme in the presence of camptothecin at concentrations of
0.05, 0.1, 0.25, 0.5, and 1 mM, respectively. The relaxation assay
in a cell-free system was performed as described in Materials and
methods. (IC50 [campt., topo I ] = 0.29 mM).

1, and 2 mM) in cell-free systems using the relaxation
assay (Figures 3 and 4). The maximum soluble dose of
bortezomib was 2 mM. Bortezomib showed a very weak
inhibition effect on human topoisomerase I enzyme (IC50
= 87.11 mM) as seen in Figure 3. However, the IC50 value
of bortezomib on human topoisomerase I enzyme was not
in the range of tested concentrations. The IC50 value was
calculated by plotting the percentage of inhibition versus
the concentrations by using the S-probit program. On the
other hand, the inhibitory effect of bortezomib on human
topoisomerase II enzyme (IC50 = 1.41 mM) was strong, as
seen in Figure 4.
In this study, we applied bortezomib in combination
modes with topoisomerase I inhibitor camptothecin and
topoisomerase II inhibitor etoposide. As a result, in both
cases synergistic effects were observed (Figures 5 and 6).
4. Discussion
In recent years, the outcome of multiple myeloma patients
has been significantly improved due to the discovery of
novel antimyeloma agents together with better knowledge
of the pathophysiology of the disease. Among them, the
proteasome inhibitor bortezomib (Velcade) represents an
excellent drug that has quickly moved from the bench to
the bedside and exhibits powerful antimyeloma activity.
Nowadays, bortezomib-based therapies are suggested
as standards of care in patients with newly diagnosed
and relapsed multiple myeloma. However, intrinsic and

ÖKSÜZOĞLU et al. / Turk J Med Sci

1

2

3

4

5

6

1

2

3

4

5

6

7

Figure 2. The inhibitory effect of etoposide on human
topoisomerase II. Lane 1: supercoiled pBR322 plasmid DNA (0.3
µg) without enzyme. Lane 2: plasmid DNA with 3 units of topo II
enzyme (control). Lanes 3–6: plasmid DNA with 3 units of topo
II enzyme in the presence of etoposide at concentrations of 0.75,
1.5, 3, and 6 mM, respectively. The relaxation assay in a cell-free
system was performed as described in Materials and methods
(IC50 [etop, topo II ] = 3.77 mM).

Figure 3. The inhibitory effect of bortezomib on human
topoisomerase I. Lane 1: supercoiled pBR322 plasmid DNA (0.3
µg) without enzyme. Lanes 2 and 3: plasmid DNA with 3 units of
topo I enzyme (control). Lanes 4–7: plasmid DNA with 3 units
of topo I enzyme in the presence of bortezomib at concentrations
of 0.25, 0.5, 1, and 2 mM, respectively. The relaxation assay in
a cell-free system was performed as described in Materials and
methods (IC50 [bort., topo I] = 87.11 mM).

acquired resistance to bortezomib and toxicities may limit
its efficacy (24). The discovery and development of new
treatments are urgently needed due to the problems of
current treatment, such as toxicities and drug-resistance.

Drug combination is the most widely used approach in
treating numerous dreadful diseases, such as cancer. The
main aims are to achieve synergistic therapeutic effects
and dose and toxicity reductions, and to minimize or delay
the induction of drug resistance (16). Most cancers have
multiple genetic alterations and molecular abnormalities.
It is seldom very useful to use only one anticancer drug
owing to refractory and drug resistance of cancer tissues.
Using anticancer drugs in combinations instead of
singly might dramatically promote the control of cancer
progresses and metastasis in different patients (25).
Combination therapy has been the standard of care,
especially in cancer treatment, since it is a rationale
strategy to increase response and tolerability and to
decrease resistance. Currently, there is growing interest
in combining anticancer drugs aiming at maximizing
efficacy while minimizing toxicity through the delivery of
lower drug doses (26,27).
There are a limited set of principles that underlie drug
combinations in cancer treatment. Briefly, the drugs used
in combination should possess the following features:
to use drugs with nonoverlapping toxicities so that each
drug can be administered at near-maximal dose; combine
agents with different mechanisms of action and minimal
cross-resistance in order to inhibit the emergence of
broad spectrum drug resistance; preferentially use drugs
with proven activity as single drugs and administer the
combination at early stage disease and at a schedule with
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Figure 4. The inhibitory effect of bortezomib on human
topoisomerase II. Lane 1: supercoiled pBR322 plasmid DNA (0.3
µg) without enzyme. Lane 2: plasmid DNA with 3 units of topo
II enzyme (control). Lanes 3–6: plasmid DNA with 3 units of
topo II enzyme in the presence of bortezomib at concentrations
of 0.25, 0.5, 1, and 2 mM, respectively. The relaxation assay in
a cell-free system was performed as described in Materials and
methods (IC50 [bort., topo II ] = 1.41 mM).
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Figure 5. The combined effects of bortezomib and camptothecin
on human topoisomerase I. Lane 1: supercoiled pBR322 plasmid
DNA (0.3 µg) without enzyme. Lane 2: plasmid DNA with 3 units
of topo I enzyme (control). Lanes 3–6: plasmid DNA with 3 units
of topo I enzyme in the presence of bortezomib and camptothecin
at concentrations of 2 mM bort. + 1 mM camp., 1 mM bort. + 0.5
mM camp., 0.5 mM bort. + 0.1 mM camp., and 0.25 mM bort.
+ 0.05 mM camp., respectively. The relaxation assay in a cell-free
system was performed as described in Materials and methods.

Figure 6. The combined effects of bortezomib and etoposide on
human topoisomerase II. Lane 1: supercoiled pBR322 plasmid
DNA (0.3 µg) without enzyme. Lane 2: plasmid DNA with 3 units
of topo II enzyme (control). Lanes 3–6: plasmid DNA with 3 units
of topo II enzyme in the presence of bortezomib + etoposide at
concentrations of 0.25 mM bort. + 0.75 mM etop., 0.5 mM bort.
+ 1.5 mM etop, 1 mM bort. + 3 mM etop., and 2 mM bort. + 6
mM etop., respectively. The relaxation assay in a cell-free system
was performed as described in Materials and methods.

a minimal treatment-free period between cycles but still
allowing the recovery of sensitive target tissues (26,27).
Nowadays, drugs combination studies for cancer
therapy have been tried by many researchers (24,28–30).
Combinations of topo I inhibitor camptothecin and topo
II inhibitor doxorubicin have been found to synergistically
inhibit cancer cell growth in vitro (28). Etoposide and
cisplatin is the most used combination chemotherapy
regimen in extensive-stage disease small-cell lung cancer
and usually achieves a high initial response rate (29).
Combination studies of bortezomib with various
anticancer drugs, including dexamethasone, DNAdamaging drugs (such as melphalan, cyclophosphamide,
and doxorubicin), thalidomide, and lenalidomide,
are currently ongoing in patients with both relapsed/
refractory and newly diagnosed multiple myeloma (24).
The triplet combination of bortezomib and thalidomide
plus dexamethasone regimen was one of the highly
effective and well tolerated induction therapies for multiple
myeloma patients (30).
Over the past decade, new insights into the biology
of multiple myeloma have provided the framework for
the development of novel therapies to overcome drug
resistance. Remarkable activity seen with bortezomib as a
single agent in advanced refractory or relapsed multiple
myeloma has validated proteasome as an effective target

in the treatment of cancer and has led to approval for
bortezomib use in patients for whom prior therapies have
failed. Based on preclinical and clinical data demonstrating
that bortezomib adds to the anticancer activity of other
chemotherapeutic drugs, studies of combination therapies
have been initiated more recently in patients with both
refractory/relapsed and newly diagnosed multiple myeloma
in an attempt to expand the therapeutic armamentarium
for this still-devastating malignancy. Studies similar to
these will provide important information concerning the
best combination of drugs and, it is hoped, will soon reveal
the optimal treatment strategies to improve the prognosis
of patients with cancer (24).
In the present study, bortezomib was applied in
combination with topoisomerase I inhibitor camptothecin
and topoisomerase II inhibitor etoposide. These inhibitors
are widely used antitumor drugs that were approved by
the FDA for the treatment of various cancers. However,
the combined applications of these drugs were not studied
sufficiently. For this reason, we investigated their combined
implementations and, as a result, in both cases synergistic
effects were observed. When applied alone 0.5 mM
bortezomib and 0.1 mM camptothecin were ineffective on
topoisomerase I (Figures 1 and 3) while they were effective
when used in combination at these concentrations (as
seen from lane 5 of Figure 5). Likewise, 1 mM bortezomib
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and 3 mM etoposide were found to be ineffective when
applied alone on topoisomerase II enzyme (Figures 2 and
4) while they were effective when used in combination at
these concentrations (as seen from lane 5 of Figure 6). Our
results suggest that bortezomib possesses an increased
effect at lower doses when used in combination with
topoisomerase I and II inhibitor drugs than when used
alone. After all, the observation of synergistic effects of the
drugs with maximizing efficacy while minimizing toxicity
through the delivery of lower drug doses indicates that
combinations of these drugs can be tried in future in vivo
applications.
Taken together, our data demonstrated that
bortezomib is effective not only on proteasome but also

on topoisomerase II. In addition, the combined use of
proteasome inhibitor bortezomib with topo I inhibitor
camptothecin or topo II inhibitor etoposide exhibited a
synergistic effect on the inhibition of human topoisomerase
enzymes. Combinations of these drugs are more effective
than any single drug. The results of this study indicate that
these data may build a framework for combination studies
with bortezomib, camptothecin, and etoposide in the
treatment of cancer.
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